32.72
+0.8863(+2.78%)
Currency In USD
| Previous Close | 31.83 |
| Open | 32.07 |
| Day High | 33.04 |
| Day Low | 31.82 |
| 52-Week High | 33.47 |
| 52-Week Low | 13.36 |
| Volume | 30,410.67 |
| Average Volume | 257,306 |
| Market Cap | 938.13M |
| PE | -10.45 |
| EPS | -3.13 |
| Moving Average 50 Days | 26.39 |
| Moving Average 200 Days | 21.06 |
| Change | 0.89 |
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
GlobeNewswire Inc.
Mar 09, 2026 12:00 PM GMT
Dr. Robert Lenz brings over 20 years of experience in neuroscience drug developmentNEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company de
LB Pharmaceuticals to Participate in Upcoming March Investor Events
GlobeNewswire Inc.
Mar 04, 2026 9:05 PM GMT
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatmen
LB Pharmaceuticals Announces $100.0 Million Private Placement
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsych